Skip to content

Welcome to Discover Pharma! Today is : November 11, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Research & Development

  • Digital & Data,Drug Discovery & Development,Research & Development

    bit.bio launches cell culture media kits for human cell research

    bit.bio has launched two cell culture media kits designed to [...]

    July 6, 2026
  • Opinion & Events,Research & Development,Therapeutic Areas

    Halving fertility treatment costs could more than double ART births, study finds

    Reducing patient out-of-pocket fertility treatment costs by half could increase [...]

    July 7, 2026
  • Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Research & Development

    First patients dosed in Phase 1 trial of DLL3-targeted radiopharmaceutical for small cell lung cancer

    The first patients have been dosed with MP0712, a DLL3-targeted [...]

    July 3, 2026
  • Central Nervous System,Drug Discovery & Development,Research & Development

    CONNECTA highlights Fragile X data as Phase 2a trial advances

    CONNECTA Therapeutics will present preclinical data supporting its Phase 2a [...]

    July 3, 2026
  • Clinical & Regulatory,Medical devices,Research & Development

    Xeltis passes halfway mark in US trial of haemodialysis vascular access device

    Xeltis has passed the halfway enrolment mark in its US [...]

    July 3, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    Abivax reports positive Phase 3 maintenance data for obefazimod in ulcerative colitis

    Abivax has reported positive topline results from Part 2 of [...]

    July 3, 2026
  • Digital & Data,Research & Development,Therapeutic Areas

    Fleming Initiative selects AWS to support global antimicrobial resistance platform

    The Fleming Initiative has selected Amazon Web Services (AWS) to [...]

    July 3, 2026
  • Digital & Data,Research & Development,Therapeutic Areas

    Study supports home-based EEG platform for Alzheimer’s clinical trials

    A peer-reviewed study has demonstrated that Cumulus Neuroscience’s NeuLogiq platform [...]

    July 3, 2026
  • Clinical & Regulatory,Pharmaceuticals and therapeutics,Research & Development

    FDA backs Telix Phase 3 ProstACT trial expansion into US

    Telix Pharmaceuticals has received FDA agreement on the protocol and [...]

    July 3, 2026
  • Clinical & Regulatory,Digital & Data,Pharmaceuticals and therapeutics,Research & Development

    Remepy study links Hybridopa brain changes to improved Parkinson’s outcomes

    Remepy has published new peer-reviewed findings showing that its investigational [...]

    July 2, 2026
Previous202122Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Resolution Therapeutics completes Phase 1/2 RTX001 liver disease trial dosing
    Categories: Advanced Therapies, Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
  • Eleva separates biologics platform from Factor H therapy
    Categories: Advanced Therapies, Biotech & Pharma Business, Pharmaceuticals and therapeutics, Research & Development
  • ENA Respiratory begins Phase 2a dosing of nasal antiviral INNA-051
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details.
OK
Go to Top